April 26, 2022
Ambagon Therapeutics Appoints Gideon Bollag, Ph.D., to Scientific Advisory Board
January 6, 2022
Ambagon Therapeutics Launches with $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline
In The News
Michael J. Fox Foundation for Parkinson's Research | April 8, 2023
Ambagon and academic collaborators awarded grant from the Michael J Fox Foundation to study 14-3-3:LRRK2 stabilizers as a neuroprotective therapy for Parkinson’s Disease.
BioCentury | January 5, 2023
2022 Class of Emerging Companies
BioSpace | January 4, 2023
Top Life Sciences Startups to Watch in 2023
BioCentury | February 1, 2022
Ambagon: creating molecular glues for disordered proteins
Publications & Presentations
Molecular glues to stabilise protein-protein interactions
Current Opinion in Chemical Biology. 2022.
Macrocycle-stabilization of its interaction with 14-3-3 increases plasma membrane localization and activity of CFTR
Nat Commun. 2022.
Reversible Covalent Imine-tethering for Selective Stabilization of 14-3-3 Hub Protein Interactions
J. Am. Chem. Soc. 2021
Structure-based Evolution of a Promiscuous Inhibitor to a Selective Stabilizer of Protein–protein Interactions
Nat Commun. 2020
Site-directed Fragment-Based Screening for the Discovery of Protein–protein Interaction Stabilizers.
J. Am. Chem. Soc. 2019